Antioch University

AURA - Antioch University Repository and Archive
Antioch University Full-Text Dissertations &
Theses

Antioch University Dissertations and Theses

2022

The Caregiver’s Experience of Post-Treatment Lyme Disease
Syndrome
Jordyn Deschene

Follow this and additional works at: https://aura.antioch.edu/etds
Part of the Clinical Psychology Commons, and the Psychiatric and Mental Health Commons

THE CAREGIVER’S EXPERIENCE OF POST-TREATMENT LYME DISEASE
SYNDROME

A Dissertation

Presented to the Faculty of
Antioch University New England

In partial fulfillment for the degree of
DOCTOR OF PSYCHOLOGY
by

Jordyn Graves Deschene
ORCID Scholar No. 0000-0003-1138-6132

October 2021

THE CAREGIVER’S EXPERIENCE OF POST-TREATMENT LYME DISEASE
SYNDROME

This dissertation, by Jordyn Graves Deschene, has
been approved by the committee members signed below
who recommend that it be accepted by the faculty of
Antioch University New England
in partial fulfillment of requirements for the degree of

DOCTOR OF PSYCHOLOGY

Dissertation Committee:

Karen Meteyer, PhD, Chairperson

Christina Tempesta, PsyD

Nancy Ruddy, PhD

ii

Copyright © 2021 by Jordyn Graves Deschene
All Rights Reserved
iii

ABSTRACT
THE CAREGIVER’S EXPERIENCE OF POST-TREATMENT LYME DISEASE
SYNDROME
Jordyn Graves Deschene
Antioch University New England
Keene, NH
As the rate of Lyme disease diagnoses increases in the United States, it can be assumed that the
frequency at which post-treatment Lyme disease syndrome (PTLDS) is diagnosed will also
increase. While research has been published on the experience of caregivers of other chronic
illnesses, no studies have examined the experience of the PTLDS caregiver. This quantitative
study sought to discover the most significant burdens, mental health status (levels of anxiety and
depression), and level of invalidation experienced by the PTLDS caregiver. Thirty individual
participants took part in this study. This study found that mental burden is a significant area of
concern for PTLDS caregivers, that increased PTLDS symptomology is associated with
increased financial concern, and that PTLDS caregivers endorsed a high rate of anxiety and
depression symptoms related to the diagnosis. Invalidation did not appear to be experienced by
the PTLDS caregiver in this sample. This study has clinical implications for medical
professionals as they should be aware of the potential impact of medical invalidation, financial
concern, and the burdens and mental health of the PTLDS caregiver. This dissertation is
available in open access at AURA (https://aura.antioch.edu) and OhioLINK ETD Center
(https://etd.ohiolink.edu).
Keywords: Lyme disease, post-treatment Lyme disease, caregiving, quality of life, caregiver
burden, invalidation, mental health
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CHAPTER I: INTRODUCTION
The Centers for Disease Control and Prevention (CDC) estimates that roughly 300,000
people are diagnosed with Lyme disease each year (Johnson et al., 2014). This is 1.5 times the
number of women diagnosed with breast cancer and six times the number of people diagnosed
with HIV/AIDS. An infection from bacteria in black-legged ticks causes Lyme disease and, if
left untreated, can produce a variety of pathological symptoms (Maloney, 2016). Interestingly,
some individuals are treated for Lyme disease and experience long-term atypical manifestations
of the disease. This condition, known as post-treatment Lyme disease syndrome (PTLDS), is
estimated to affect as many as 5–30% of individuals diagnosed and treated for Lyme disease
(Johnson et al., 2014). The symptoms of PTLDS affect a broad range of functional areas and can
seriously disrupt the quality of life for the individual. Furthermore, due in part to the
manifestation of symptoms resembling other autoimmune conditions, PTLDS is not widely
accepted in the medical community, which has the potential to increase medical invalidation in
the PTLDS patient. While there is some research on the experience of post-treatment Lyme
disease syndrome, a survey of the literature has shown that there is very little written about the
experience of the caregivers of individuals with PTLDS. The purpose of this study was to learn
what the most significant caregiver burdens are for PTLDS caregivers, what their mental health
status is, and how—if at all—invalidation from the medical community affects their overall
burden and mental health.
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CHAPTER II: LITERATURE REVIEW
Lyme Disease
Lyme disease (LD) is a multi-staged tick-borne illness which frequently produces
multisystemic illness (Maloney, 2016). In the United States, patients diagnosed with LD have
contracted the bacterial agent Borrelia burgdorferi from black-legged (deer) ticks. The early
stage of LD is localized to the skin, with symptoms and signs usually appearing within 2 to 30
days of a bite. This stage's hallmark manifestation—showing up in 70% of cases—is the
expanding erythema migrans (EM) rash, also known as the “bullseye” rash. In the United States,
EM is frequently accompanied by flu-like symptoms, such as malaise and fatigue, headache, and
fever (Steere et al., 2004). The late stage of LD is defined by the bacterial agent spreading to
other body sites (Maloney, 2016). The dissemination of the bacteria can occur soon after the bite,
yet the symptoms and signs indicating the later stage of LD may not appear for weeks, months,
or years after the initial infection. Both early and late-stage LD are treated with antibiotics, but
treatment outcomes are highly variable, and a patient’s response is impossible to predict. If left
untreated, patients with this infection begin to experience intermittent arthritis, and United States
studies have shown a rare late neurologic syndrome characterized by subtle cognitive
disturbances and spinal radicular pain (Steere et al., 2004).
Post-treatment Lyme Disease Syndrome
PTLDS is often referred to and used interchangeably with the terms, Chronic Lyme
Disease, Persistent Lyme Disease, and Post-Lyme Syndrome. This study will be using the term
PTLDS to characterize participants who have been treated for Lyme Disease and are continuing
to experience symptoms. While this term will continue to be used in this research paper as it is
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the appropriate medical term, it was discovered through the recruitment process that this term is
not accepted among the PTLDS population due to the word “syndrome.” It was advised that the
survey begin using the term Chronic Lyme Disease in the process of recruiting participants.
Additionally, please note that when LD is used, it means explicitly Lyme Disease and not
post-treatment Lyme Disease. This distinction is important because the term PTLDS indicates
that the patient has been diagnosed and treated for Lyme disease and is still experiencing
symptoms despite the treatment versus patients suffering from undiagnosed or untreated Lyme
disease.
PTLDS describes the attribution of various atypical symptoms to the bacterial infection
that causes LD (Lantos, 2015). These are categorized as atypical symptoms for LD in that they
lack the clinical abnormalities that are well recognized in LD, and, in many cases, there is an
absence of both serologic evidence and plausible exposure to the LD infection. The symptoms
typically associated with a diagnosis of PTLDS include, but are not limited to, chronic pain,
fatigue, neurocognitive and behavioral symptoms, as well as alternative medical diagnoses,
which are the most common neurologic and rheumatologic diseases (Lantos, 2016). Patients with
PTLDS may develop disabling musculoskeletal pain, neurocognitive difficulties, fatigue, or a
combination of symptoms (Steere et al., 2004). These symptoms strongly resemble those
experienced in chronic fatigue syndrome or fibromyalgia and can persist for months or years
after standard antibiotic treatment. The critical distinction between LD and PTLDS is that
patients with PTLDS have been treated with antibiotics unsuccessfully, which allows the disease
to continue living in the body (CDC, 2019; Steere et al., 2004). Of those diagnosed and treated
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for LD promptly, studies have reported a wide range—5–30%—of the proportion that experience
PTLDS (Johns Hopkins Medicine Newsroom, 2019).
Diagnosing PTLDS
The challenge in diagnosing PTLDS is real and legitimate as LD manifests as an
autoimmune disorder. Autoimmune diseases encompass a wide variety of disorders, ranging
from those that are acute and spontaneously regressive to those that are more chronic conditions
(Bach, 2012). The etiology of autoimmune disease has not been well established, but there is
overlap in the presentation of symptoms. These are most commonly joint and muscle pain,
general muscle weakness, possible rashes and low-grade fever, numbness and tingling, shortness
of breath, and heart palpitations. However, it is important to note that the combination of
symptoms experienced by those with PTLDS is different from those seen in autoimmune
diseases such as lupus, fibromyalgia, and other diseases, such as chronic fatigue syndrome, and
depression.
A wide range of different symptoms can be found in PTLDS. Cairns and Godwin (2005)
conducted a meta-analysis of the symptoms commonly associated with PTLDS. The five studies
used in the meta-analysis looked at the occurrence of 10 symptoms persisting for 3–6 years after
onset and initial treatment of the infection. The 10 symptoms included fatigue (one symptom),
musculoskeletal pain (three symptoms: joint or muscle pain, muscle aches, and swollen joints),
and neurocognitive difficulties (six symptoms: memory problems, poor concentration,
difficulties in formulating ideas, difficulties in word finding, difficulties in judgment, and
difficulties naming objects). The results showed that fatigue and all three musculoskeletal
symptoms were significantly more frequent in patients diagnosed and treated with LD than
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control subjects. Four neurocognitive difficulties were more frequent in patients with LD. As
mentioned above, while there is some symptom overlap between LD and autoimmune diseases
and other disorders, it can seem as though the PTLDS patient suffers from multiple of these
diagnoses at once. This study shows a definitive connection between LD and a distinct set of
persistent symptoms known as PTLDS which impact a person’s life significantly.
Impact on Quality of Life
Given what is known about the symptomology of PTLDS, it becomes pertinent to
consider what the quality of life is for those who are suffering from this chronic illness. Chronic
medical conditions are characterized in various ways, and because these conditions come with
varying levels of severity, it makes comparing the illnesses challenging (Johnson et al., 2014).
Fortunately, the CDC developed a standardized 9-item survey known as the Health-Related
Quality of Life (HRQoL) metric (as cited in Johnson et al., 2014). The results of a study
comparing the HRQOL metrics of patients with PTLDS to those with other chronic illnesses
(e.g., congestive heart failure, fibromyalgia, stroke, heartache, etc.) show that those with PTLDS
have a significantly worse quality of life. When looking at how patients with PTLDS are affected
throughout 30 days, it has been found that they experience the most severe symptoms for
upwards of 55% of the days and experience overall symptoms nearly every day. Patients with
PTLDS reported experiencing healthy days with vitality a mere three days of the 30 days
(Johnson et al., 2014).
Children With PTLDS
PTLDS has also been known to manifest in children as well as adults. A controlled study
done by Tager et al. (2001) compared 20 children with PTLDS to 20 healthy control subjects and
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found that the Lyme sample had significantly more psychopathology and more objective
cognitive deficits than the control group. Children with PTLDS had higher rates of anxiety,
mood, and behavioral disorders than children without PTLDS, and they also had more difficulty
learning and focusing attention. On caregiver-report forms, parents indicated that their PTLDS
child had learning and attention problems, feelings of ineffectiveness, and mood problems. This
is of particular importance because children with PTLDS who present with psychiatric problems
may be misdiagnosed with having a primary psychological condition such as affective disorder,
attention-deficit/hyperactivity disorder, or oppositional defiant disorder. Compared to the
control group, children with PTLDS had cognitive deficits (e.g., visual and auditory attention,
working memory, and mental tracking) as defined by both objective measures of cognitive
functioning and self-report measures.
As outlined above, PTLDS is a significant disorder that brings about a variety of
debilitating symptoms in both children and adults. What compounds the severity of this disorder
is that it is not widely acknowledged in the medical community, and patients are often told that
another disorder causes their symptoms. There is more information regarding this in the
invalidation section, but it is important to note that feelings of invalidation can intensify the
experience of these symptoms and have the potential to increase the burden of the PTLDS
caregiver (Rebman et al., 2015).
Controversy
On top of dealing with the physical and emotional suffering that comes with PTLDS,
patients are also faced with several controversies surrounding the diagnosis (Maloney, 2016).
First and foremost is that the existence of PTLDS is not agreed upon unanimously in the medical
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field. While some medical professionals believe in PTLDS, there is a significant gray area when
discussing PTLDS. Some doctors believe that the post-treatment symptoms reported after an
early diagnosis of LD are people reporting symptoms that are commonly seen in the general
population or those of a secondary condition such as chronic fatigue syndrome or fibromyalgia.
Other doctors believe that the post-treatment symptoms represent a failure in earlier treatment.
Another element of controversy stems from pseudoscientific and alternative treatment
practitioners spurring legislative efforts to subvert evidence-based medicine and peer-reviewed
science (Auwaerter et al., 2011; Soucheray, 2017; Sun, 2019). These medical providers may be
viewed as taking advantage of Lyme patients who are desperate to find symptom relief and
charge them massive amounts of money for non-evidence-based treatments. As Auwaerter and
colleagues (2015) outlined in their review, anti-science LD treatments have included the use of
UV rays, essential oils, hyperbaric oxygen, chelation therapy, photon therapy, and many others.
Furthermore, several deaths have been linked to LD patients being injected with toxic substances
(Auwaerter et al., 2011).
Adding to the confusion is that, until recently, none of the clinically available tests for
LD could determine whether a patient has an ongoing infection after treatment (Maloney, 2016).
There is no evidence in any of the areas associated with LD—including blood, joints, etc.—that
an individual is still infected. This leads many professionals to conclude that the patient’s
symptoms are therefore attributable to another medical condition, even though studies have
shown that there are no diseases that encapsulate all the symptoms experienced by patients with
PTLDS (Cairns & Godwin, 2005). Mechanisms that can explain the symptoms of PTLDS
include the presence of other untreated infections, permanent or temporary tissue damage, and
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persistent bacterial infection (Maloney, 2016). Regardless of the cause of their symptoms,
patients with PTLDS experience great personal suffering and often feel as though the medical
community has failed to effectively explain or treat their illness (Lantos, 2016).
However, promising research coming out of Johns Hopkins University (2019) may
indicate emerging diagnostic capabilities for PTLDS. In a small study, researchers compared 12
patients with documented PTLDS, and they all showed widespread brain inflammation compared
to 19 healthy control subjects. These results have been interpreted to suggest that brain
inflammation from LD may continue in the brain after treatment. This may explain why it has
been impossible to detect markers of Lyme in the joints and blood (not including endorsing joint
pain) and why PTLDS patients suffer a wide variety of cognitive and physiological symptoms.
This technique is still in its infancy, and as such, it is not widely available as a diagnostic tool
yet. Diagnostic tools notwithstanding, patients with PTLDS and their caregivers continue to
experience invalidation from the medical community for various reasons.
Invalidation
When considering how a disease can be debilitating mentally and physically, it is easy to
take for granted what it means to have a confirmed diagnosis. A PTLDS diagnosis proves to be a
complex challenge for physicians (Rebman & Aucott, 2020). Meanwhile, the lived experience of
the PTLDS patient is marked by uncertainty and often illness invalidation. The PTLDS patient
may be forced to re-negotiate physical and social identities to the “new normal” of chronic
illness, often without the same level of medical support and certainty afforded to patients with
conditions that are not contested (Rebman et al., 2015). There is debate about why this
phenomenon occurs, but leading theories state that patients often over-endorse symptom
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experience when they feel they are not believed (Merckelbach et al., 2019). As devastating as
PTLDS is for the person who has the diagnosis, it also can affect the physical and mental health
of the person caring for them. There is scant research that focuses on the invalidation
experienced by PTLDS patients and their caregivers.
Caregivers
The term caregiver refers to an unpaid family member, friend, or neighbor who provides
care to an individual with an acute or chronic condition and needs assistance to manage different
tasks (Reinhard et al., 2008). Caring for individuals with chronic illnesses can lead to various
pathological symptoms, including stress, depression, anxiety, and compassion fatigue
(del-Pino-Casado et al., 2019; Pinquart & Sorensen, 2003). The psychological well-being and
physical health of caregivers have been noted to be worse than individuals who are not
responsible for taking care of another person (del-Pino-Casado et al., 2019). There are also many
positive impacts of caregiving including feeling a sense of meaning and purpose in caring for a
loved one (Semiatin & O’Connor, 2012). There is limited research available on caregivers’
experiences with PTLDS, and much of the reported information comes from support websites
and articles rather than peer-reviewed sources. However, given what is known about the quality
of life of individuals with PTLDS, it is hypothesized that the burdens experienced by PTLDS
caregivers are similar to caregivers of patients with other chronic illnesses.
Caregiver Burden
Individuals caring for others with chronic illnesses experience a variety of symptoms.
Day and Alston (1988) looked at the overall stress and stress levels experienced in different areas
for caregivers of adults with physically disabling chronic illness (Bevans & Sternberg, 2012;
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del-Pino-Casado et al., 2019). They found a trend for caregivers of adults to have increased
overall stress and more significant stress related to lack of personal reward, terminal illness
stress, physical limitations, and preference for institutional care. Another study found that some
caregivers experience exacerbation of their own physical and mental health concerns while
caring for the ill individual and endorse negative experiences of support and describe the
uncertainty of how to obtain said support (Noonan et al., 2018). These factors are crucial when
considering the impact PTLDS has on caregivers due to the lack of support that is generally
associated with a PTLDS diagnosis. Furthermore, many of the symptoms associated with PTLDS
(cognitive fog, joint pain, lethargy, etc.) are often associated with aging; and as such, caregivers
can expect similar outcomes to caregiving for the elderly when tending to PTLDS patients.
Emphasizing the results mentioned in the previous paragraph is a 2017 study conducted
by the American Association of Retired Persons (AARP) in which they published data
highlighting the adult caregiver’s experience of tending to an older adult (age 50+) family
member (Skufca, 2017). While family caregivers reported that positive emotions far outweigh
the negative, they also reported feeling unprepared to take on the caregiver role and being
stressed, worried, and overwhelmed. In addition to mental challenges, caregivers also described
personal challenges surrounding caring for their household, tending to their health, and a
reduction in the amount of money they can save (Gardiner et al., 2020; Schulz & Eden, 2016). In
addition to experiencing several negative emotions, about a quarter of the caregivers expressed
regrets or wish they had done something different regarding caring for their family member.
While caregiving is challenging across the board, tending to someone with a chronic illness
yields its own set of concerns.
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Caregivers of Individuals With Chronic Illness
In 2004, Lim and Zebrack published a meta-analysis of 19 studies on the quality of life
for family caregivers helping those with chronic physical illness. The analysis found that family
caregiving means increased financial, physical, and emotional responsibility. Caregivers deal
with extensive coordination of care, including symptom management, disability, mobility, and
dressings. Lim and Zebrack (2004) also found that caregivers often feel tired, isolated, and
overwhelmed because they lack support, training, information, and a sympathetic ear.
Additionally, caregivers who are employed report having to miss work, take personal days, or
quit or retire early to provide care. Chronic illness affects the lives of those suffering from
disease and those of the family members or loved ones who care for them. Family caregivers'
physical and emotional health can influence the health-welfare and successful rehabilitation of
persons with chronic illness. The effects on caregivers’ lives are physical, psychological, and
social and may include worsened physical health, impaired social and family life, and increased
stress, anxiety, and depression.
Caregivers of Children With Chronic Illness
Childhood chronic illness often impacts the entire family system (Cousino & Hazen,
2013). For parents, the devastating news of their child’s diagnosis, the associated medical risks
and cost, and the potential for a shortened life expectancy can impact their mental and physical
well-being. Adding to the jarring nature of a chronic diagnosis are the demanding treatment
regimens, shifts in roles, responsibilities, and resources, all of which can negatively impact
family functioning. Caregivers of children with chronic illnesses endorse more significant
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general parenting stress than caregivers of healthy children (Cohn et al., 2020; Cousino & Hazen,
2013; Day & Alston, 1988).
Additionally, while advances in medical care have improved the survival of children with
chronic and critical illnesses, it also increases the financial strain experienced by the family
(Thomson et al., 2016). Caregivers of children with chronic illnesses can spend thousands of
dollars on out-of-pocket costs. This, coupled with the fact that many caregivers must stop
working, tends to increase financial burden. Chronic, multisystemic diseases are associated with
functional limitations as well as a need for care provided across multiple clinical specialties
(Thomson et al., 2016). This is especially true for unidentified medical conditions and can lead to
an increase in referrals and appointments. Often, caregivers spend time battling insurance
companies as well because of the lack of a diagnosis that could explain the presenting symptoms
(Thomson et al., 2016). There were no studies which showed if early onset of PTLDS leads to
worse symptoms, but it does appear that it is the chronicity of symptoms in children that
increases caregiver stress.
Caregivers and Invalidation
Research on the impacts of invalidation is still in the early stages compared to other
external factors, but the available research shows just how vital validation can be in a patient’s
care, quality of life, and recovery (Lobo et al., 2014). Based on available literature, it is reasoned
that invalidation of a condition will also impact the mental health and overall burden of
caregivers because of how invalidation affects the person they are taking care of and how it
impacts them directly.
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Benefits of Caregiving
While the history of caregiver literature has focused around stressors, consequences, and
the best methods to manage them, recent literature has shifted to focusing on the positive aspects
of caregiving (Zarit, 2012). In research done by Folkman (1997, 2007), it was found that positive
and negative emotions occur concurrently during periods of high stress. Folkman proposed that
introducing meaning-focused coping strategies allowed caregivers to reframe the large and small
events in their life, allowing them to look at their life in a more positive way. Furthermore,
Fredrickson (2001) demonstrated that when people experience positive feelings, their perspective
is broadened. During periods of chronic stress, narrowing their perspective may cause caregivers
to overlook practical strategies for managing their situation, while experiencing positive
emotions may lead to more adaptive coping skills.
Positive and negative emotions could occur simultaneously during periods of high stress
(Folkman 1997, 2007), which could potentially allow caregivers to focus on the benefits of
caregiving rather than adverse impacts. Among benefits are inner personal growth, increased
beliefs about self-efficacy, strengthened relationships, feeling appreciated, and increased esteem
(Contador et al., 2012; Semiatin & O’Connor, 2012). Increased beliefs about self-efficacy may
lead to more positive views of one’s caregiving experience and less subjective stress (Semiatin &
O’Connor, 2012). In 2012, research done by Mackenzie and Greenwood showed that positive
experiences among caregivers were associated with coping strategies. While caregiving can be
profoundly fulfilling, it can also be overwhelming, and caregivers should be given the resources
to mitigate future issues (Sullivan & Miller, 2015).
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Providing Caregiver Resources
Despite the possibility of positive impacts, past research suggests that the burden of
caregiving has a significant impact on the individual caregivers and can also lead to a
deterioration in family functioning (Toledano-Toledano & Dominguez-Guedea, 2019). By not
mitigating caregiver burden, the likelihood of future mental and physical illness is increased
(Schulz & Sherwood, 2008). Caregivers tend to experience depression and distress first,
followed by physiologic changes and impaired habits that ultimately lead to further illness. This
impairment of quality of life leads to high socioeconomic costs for healthcare systems and
society (Oliva-Moreno et al., 2008), including, but not limited to, direct medical costs, direct
non-medical costs, and loss of labor productivity. While caregivers are generally offered
resources by medical providers, there may be some illnesses where providing resources may not
be standard practice, which may be the case with PTLDS caregivers (Thomas, 2017).
Caregivers and Lyme
The literature on caregiving is extensive, and there have been numerous studies done on
the impact of caregiving for the elderly, those with specific and general chronic conditions, etc.
However, there is a significant gap in the literature on the experience of the PTLDS caregiver. It
is unclear why this gap in the literature exists, but it seems likely that ambiguous
testing/diagnosis and stigma of a PTLDS diagnosis have something to do with it. From what is
known about the patients’ experience of PTLDS, it is expected that the overall burden of the
PTLDS caregiver is high. What remains unclear in the research are the areas in which PTLDS
caregivers feel the most burdened and how this burden affects their overall mental health (i.e.,
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anxiety and depression). Additionally, the research does not address the rate at which the medical
community invalidates PTLDS, nor how invalidation affects caregiver burden and mental health.
The current study employed a quantitative survey of the experience of PTLDS caregivers.
The questions assessed PTLDS patient symptomology, different caregiver burden areas (Burden,
Disruptiveness, Positive Adaptation, Financial Concern, and Other), invalidation, quality of life,
and the caregiver's mental health (i.e., anxiety and depression).
Research Questions
This study explored the relationship between caregiver quality of life, illness invalidation,
and caregiver mental health with the goal of addressing the following questions:
1. What are the most significant burdens for caregivers of PTLDS?
2. What is the level of anxiety and depression of PTLDS caregivers?
3. What is the level of invalidation experienced by caregivers of PTLDS?
4. Is the level of invalidation experienced by caregivers associated with overall caregiver
burden?
5. Is the level of invalidation experienced by caregivers associated with the level of
anxiety and depression of caregivers?
This study ran descriptive statistics to determine the most significant burdens, as well as
the level of overall burden, for this sample. Descriptive statistics were also run to determine the
levels of anxiety, depression, and invalidation experienced by this sample. Pearson correlations
were used to determine significant associations between scales and subscales. It was
hypothesized that caregivers would experience a high level of burden, as well as a high level of
anxiety, depression, and invalidation.
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CHAPTER III: METHOD
This study used a quantitative survey to investigate PTLDS caregivers' experience in the
areas of caregiver burden, mental health, and experiences with invalidation, and explore how
these areas related to one another. The study recruited participants via snowball sampling and by
contacting various LD groups, social media accounts, and research facilities. Emails were sent to
three research organizations, seven Lyme caregiver support groups, and nine Lyme related
accounts on Facebook and Instagram. All the participants in this study who ultimately completed
this survey were recruited on Instagram.
Participants
A total of 30 individuals participated in this study. All participants were caregivers of
PTLDS patients who had been previously diagnosed and treated for Lyme disease but who
continue to experience Lyme symptoms. On average, participants were 48 years old (SD =
11.38) and ages ranged from 29–72 years (see Table B1). The sample consisted of 100%
heterosexual women, 93% of whom identified as white or of European descent, 3.3% Hispanic
or Latinx, and 3.3% would prefer not to say. Of the 30 participants, six individuals reported that
they had no longer been able to work since becoming a caregiver for their loved one. In an
open-ended question on why they were unable to work, answers included: “[I] cannot work
while caring for three children and myself with Lyme,” “I am my daughter’s main caregiver. She
has persistent neurologic Lyme disease,” “[I am a] full-time caregiver,” “I am my 28-year-old
daughter’s fulltime caregiver. She has chronic neurologic Lyme and many co-infections,” “[I am
a] fulltime caregiver to my son with Lyme/CFS/ME.” The average age of the PTLDS individual
was 22 years (SD = 10.49) with ages ranging from 6–50. A majority (25) of the caregivers were
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parents to their loved one and the remaining (5) were either spouses, partners, or significant
others. Sixty percent of the caregivers reported that they had caregiving help with 88.9%
reporting that their spouse or co-parent provided the help. Of the 30 participants, 33.3% of them
reported that they spend over 30 hours per week caregiving for their PTLDS loved one.
Measures
The study used a Google survey to collect the data. The survey included a demographic
information questionnaire, the Horowitz Lyme Multiple Systemic Infectious Disease Syndrome
(Horowitz Lyme-MSIDS) Questionnaire, the Caregiver Quality of Life Index-Lyme scale, the
Illness Invalidity Inventory, and the Patient Health Questionnaire Anxiety and Depression Scale.
Domain specific questionnaires for caregivers are nonexistent, and as such most of these surveys
(except for the Lyme symptom questionnaire) needed to be adapted in language and some in
content. While all measures listed below are valid and reliable, it is unclear if psychometrics
holds after the necessary changes. However, Cronbach’s alpha in the current sample was run for
each adapted measure, and it appears as though liability and validity remained at acceptable
levels despite the adaptations.
Horowitz Lyme Multiple Systemic Infectious Disease Syndrome Questionnaire
The Horowitz Lyme-MSIDS Questionnaire was used to assess the PTLDS patient’s
symptom frequency. Originally a self-report form, the questionnaire was modified to reflect the
caregiver’s experience of the PTLDS patient’s symptoms. The Horowitz Lyme-MSIDS
questionnaire has been proven to have internal reliability, as well as convergent and divergent
validity (Citera et al., 2017). Cronbach’s alpha was .911 in the current sample.
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Studies have shown that the Horowitz Lyme-MSIDS questionnaire accurately
differentiates between patients with LD and healthy individuals. It should be noted that this study
added a Not Applicable (NA) option to items 7, 8, 9, and 11 as answering “None” may not
reflect the age/sex of their loved one. Additionally, for the purposes of the current study the
wording in Section 3 was changed from a self-report to a caregiver report form. For example,
item one was changed from “You have had a tick bite with no rash or flu-like symptoms” to
“Your loved one has had a tick bite with no rash or flu-like symptoms.” Overall, participants
reported a high frequency of Lyme symptoms in their loved ones (mean = 86.60; SD = 19.16)
with the lowest possible score being 30 and the highest possible score being 120.
Caregiver Quality of Life Index–Lyme scale
In order to assess the quality of life of PTLDS caregivers, the Caregiver Quality of Life
Index–Cancer (CQOLC) scale was adapted to target issues specific to caregivers of patients with
PTLDS. The CQOLC is a well-established tool designed by Weitzner et al. (1999) to assess the
distress experienced by cancer patients' caregivers. It is a 35 item self-report questionnaire that
can be completed in approximately 10 minutes. Weitzner and team (1999) established that the
CQOLC appears to possess adequate validity, retest reliability, and internal consistency and thus
proves to be a solid foundation for adapting a caregiver Lyme scale. Cronbach’s alpha was .901
in the current sample.
All the statements remained the same in the adapted Lyme scale, but an additional item
about validation was added: “I feel validated by my loved one’s health care provider.” Subscales
in the CQOLC include Burden (M = 32.90, SD = 8.49), Disruptiveness (M = 18.33, SD = 7.06,
Positive Adaptation (M = 22.93, SD = 5.22), Financial Concern (M = 10.07, SD = 4.35), and
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Other (M = 30.47, SD = 6.87). The other subscale includes items regarding sex life, sleep, feeling
validated by their loved one’s medical provider, and feeling adequately informed about their
loved one’s illness. Positive adaptation reverse scored and the added item was included in the
“other” subscale. Participants had an average score of 109.37 (SD = 22.50) which indicates a
poor quality of life associated with caregiving for a PTLDS loved one, with the lowest possible
score being 35 and the maximum being 175. Higher scores reflect lower quality of life.
Illness Invalidity Inventory
The Illness Invalidity Inventory (3*I) is an eight-item self-report form that assesses
validation levels across five environments: spouse, family, medical professionals, work
environment, and social services (Kool et al., 2010). The 3*I has been established as a reliable
and valid instrument for assessing patients’ perceptions of invalidation from different sources.
The study by Kool and team (2010) showed that patients with conditions that lack visual signs
and laboratory findings (fibromyalgia) experience greater rates of invalidation than those with
signs and findings (rheumatoid arthritis). This is particularly important as PTLDS lacks visual
signs and laboratory findings and can often be mistakenly diagnosed as fibromyalgia.
While the original objective of the 3*I was to assess validation in patients, the scale has
been adapted to target the PTLDS caregiver's experience. The wording has remained the same
except for gearing it toward the experience of the caregiver. For example, item 3 was altered
from “medical professionals give me unhelpful advice” to “medical professionals give my loved
one unhelpful advice.” Overall, participants averaged 26.2 on the 3*I which indicates a high
level of invalidation from medical professionals (SD = 7.49). The 3*I is separated into
discounting (M = 15.80, SD = 5.24) and lack of understanding subscales (M = 10.40, SD = 3.11),
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the latter of which was recoded for consistency of interpretation. Cronbach’s alpha in the current
sample was .878. Higher scores reflect greater frequency of invalidation.
Patient Health Questionnaire–Anxiety and Depression Scale
The Patient Health Questionnaire–Anxiety and Depression Scale (PHQ–ADS) combines
the nine-item Patient Health Questionnaire depression scale and the seven-item Generalized
Anxiety Disorder scale as a composite measure of depression and anxiety (Kroenke et al., 2016).
The PHQ-ADS has been established as a valid and reliable tool for assessing two of the most
common psychological conditions. Cronbach’s alpha in the current sample was .934. The
average level of anxiety and depression symptoms was 23.53 (SD = 11.66). Participants
indicated a moderately severe experience with both anxiety and depression associated with their
caregiving (M = 12.43, SD = 5.89, and M = 11.10, SD = 7.10, respectively).
Procedure
After being approved by the university’s Institutional Review Board, the survey was
disseminated via Google Forms to various Lyme caregiver support groups by email, through
social media platforms including Facebook and Instagram, and by word-of-mouth. Participants
were required to acknowledge informed consent before continuing to complete the survey.
Participants could skip any questions or measures they did not feel comfortable answering. Upon
completing the survey, results were saved anonymously in Google Forms. It should be noted that
data was collected during the COVID pandemic.
Data Analysis
Data was available for all 30 participants. Across all responses there were four missing
responses and a value of “0” was assigned to each of those items. Data collected in Google
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Forms was downloaded to SPSS and analysis was conducted within the program. Cronbach’s
alpha was calculated to measure internal consistency with all items falling in the Good to
Excellent range (.849–.936). Descriptive statistics were conducted to define and describe the
sample and variables, which will be discussed further in following sections. Additionally,
correlations between variables and measure subscales were run to determine significant
associations.
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CHAPTER IV: RESULTS
Thirty caregivers total participated in the survey. The data was checked for missing and
incomplete responses, outliers, and to gather descriptive means and standard deviations. Two
participants each had two missing responses, and a “0” was put in place of their missing
responses for those items. All other items were complete. Sum values for each measure and
subscale were calculated.
Caregiver Burden
Descriptive statistics were run on each item in the Caregiver Quality of Life-Lyme
(CQOLL) scale to assess the most significant burdens for caregivers of PTLDS loved ones
(Table B2). Total scores were computed by summing responses to the 35 items in the scale
resulting in a minimum possible score of 35 and a maximum possible score of 175. Seventy-four
percent of the items averaged at or above a 3 out of 5 suggesting that participants experienced a
high level of burden in all areas. When weighted means were calculated for each subscale,
Burden was rated highest, followed by Financial Concern, Other, recoded Positive Adaptation
(which reflected more negative adaptation), and Disruptiveness.
A Pearson correlation (Table B3) examined the relationship between overall caregiver
burden and each of the other measures and none were found to be statistically significant. A
Pearson correlation was also run to determine the relationship between each subscale of the
CQOLL and the other measures of the survey with only one significant finding. Financial
concern was found to be moderately correlated with the Lyme Symptom Questionnaire (r (28) =
.44, p = .02), suggesting that those who have loved ones with more symptom severity experience
higher levels of financial concern.
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Caregiver Mental Health
Descriptive statistics were run to determine the level of anxiety and depression
experienced by caregivers. Sum scores were computed by totaling responses to the seven-item
anxiety scale and the nine-item depression scale with a minimum number of 0 and a maximum
number of 3 for each item. Collectively, participants averaged in the moderately severe range on
both measures of anxiety and depression (M = 12.43 and 11.1, SD = 5.89 and 7.09, respectively).
On the anxiety measure, 13.33% of participants were in the mild range (0–5), 23.33% were in the
moderate range (6–10), 30% were in the moderately severe range (11–15), and 33.33% were in
the severe range (16+). On the depression measure, 23.33% were in the mild range, 36.67% were
in the moderate range, 13.33% were in the moderately severe range, and 26.67% were in the
severe range.
A Pearson correlation examined the relationship between anxiety and all measures. There
was a significant positive correlation between the caregiver quality of life and anxiety (r (28) =
.58, p < .001, R2 = .37), suggesting that 37% of the variance in quality of life is explained by
anxiety. A Pearson correlation also examined the relationship between each subscale of the
CQOLL and the anxiety scale. Caregiver Burden, Disruptiveness, and Other were found to be
moderately correlated with anxiety (r (28) = .63, p < .001, r (28) = .44, p = .02, r (28) = .55, p =
.002, respectively).
Additionally, a Pearson correlation examined the relationship between the depression
scale and the CQOLL and there was a moderate correlation found (r (28) = .39, p = .03, R2 =
.15), suggesting that 15% of the variance in quality of life is explained by depression. Depression
was also found to be moderately correlated with the Burden and Other subscales (r (28) = .38, p
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= .04, and r (28) = .43, p = .02, respectively). No other significant correlations were found.
Lower quality of life was associated with higher levels of depression in caregivers of individuals
with PTLDS.
Invalidation
Descriptive statistics were run to determine the level of invalidation experienced by
caregivers. Total scores were computed by summing responses to the eight-item invalidation
measure with a minimum score of one and a maximum score of 5 for each item. Overall,
caregivers experienced a moderate level of invalidation (M = 26.2, SD = 7.49). Additionally,
caregivers experienced discounting and lack of understanding at approximately the same level.
Pearson correlations were run to determine if the level of invalidation experienced was
associated with caregiver burden and there were no significant findings shown for the overall
measure or subscales. Pearson correlations were also run to determine if the level of invalidation
experienced by caregivers impacted their levels of anxiety and depression and no statistical
significance was found.

25

CHAPTER V: DISCUSSION
The aim of this study was to discover the most significant burdens for PTLDS caregivers,
their mental health status, and the level of invalidation they experienced. This study administered
a survey that examined Lyme symptomology in the PTLDS loved one, as well as overall
caregiver burden, anxiety and depression symptoms in caregivers, and illness invalidation
experienced surrounding the diagnosis. The main findings of this study were that mental burden
is a significant area of concern for PTLDS caregivers. Additionally, PTLDS caregivers endorsed
a high rate of anxiety and depression symptoms related to the diagnosis. While invalidation was
experienced among caregivers, there were no correlations found between invalidation and other
variables.
Caregiver Burden and Mental Health
One of the aims of the survey was to better understand what the most significant burdens
are for PTLDS caregivers. Given the mean scores on each item in the survey, the most
significant burden for PTLDS caregivers in this sample appears to be the mental toll the
diagnosis takes on the caregiver. This includes feeling upset seeing their loved one deteriorate,
increased stress, worry, frustration, mental strain, and fear of adverse treatment effects. With the
caregiver focusing on the individual with PTLDS (most commonly in this study, mothers with
children suffering from PTLDS) it limits the time they can tend to other relationships in the
family and tasks around the house, as well as participating in self-care. Furthermore, as
evidenced by the results in this survey, caregiver employment status is also affected by the
long-term nature of caregiving for PTLDS. This, coupled with diagnostic uncertainty, can lead to
significant financial concern. As mentioned above, providing caregivers with appropriate
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resources for managing their burden and stress will allow them to mitigate future issues, as well
as allow them to focus more on the positive aspects of caregiving.
Caregiver Burden and Financial Concern
One significant finding from the current study was that the financial concern subscale
was strongly correlated with the Lyme Symptom Questionnaire. This result may appear to
indicate that increased symptomology increases financial concern or that caregivers are unable to
hold jobs when caring for individuals with severe illness, for example. It should be
acknowledged that causality can go in either direction and that the results could be the result of
another factor(s). Given the set of symptoms that is typically associated with PTLDS, individuals
may need to go to a variety of doctors before the diagnosis of PTLDS is identified, if it gets
identified at all. Additionally, people with PTLDS may often try homeopathic remedies for
symptoms to find relief. These treatments are not backed by research and are often not covered
by insurance (Soucheray, 2017). As such, individuals are required to pay out-of-pocket.
Following this path also leads to the potential for caregivers and PTLDS individuals to be taken
advantage of and they may lose money due to a scheme, which inherently leads to increased
financial burden and concern.
Caregiver Mental Health
As outlined above, previous research has demonstrated that caregivers of all kinds
experience mental health issues at a greater rate than those who are not caregiving for someone.
One of the primary goals of this research study was to explore how caregivers of PTLDS were
experiencing their mental health. While the participants’ responses varied across ranges on the
anxiety and depression measure, the average of the study sample was in the moderately severe
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range. Given the correlations between lower quality of life and anxiety and depression, the
results suggest that lower quality of life is associated with more symptoms of anxiety and
depression. This may also be explained by the fact that their loved one has been diagnosed with a
chronic illness. However, it should be stated that there is a high degree of overlap between the
CQOLL and the PHQ-ADS. They were both highly correlated and tap similar constructs. Lower
quality of life was more significantly associated with depression versus anxiety symptoms
The results of this lend support to the findings of Pinquart and Sorensen (2003) in
confirming that caregivers experience a variety of pathological symptoms in response to their
caregiving duties. Given the small sample size in this study, it proves challenging to generalize
the results. However, the results seem to suggest that caregiver burden is experienced at a high
rate for PTLDS caregivers and as such, future studies should focus on large sampling and
comparing the results to caregivers of other chronic illnesses. Additionally, further research is
needed to establish appropriate interventions (psychoeducation, personal therapy, etc.)
surrounding the burdens for the PTLDS caregiver.
Invalidation
There are significant repercussions for individuals experiencing medical invalidation. As
Lobo and colleagues (2014) highlighted, validation proves to be significantly vital to the patient
experience, quality of life, and recovery. It was reasoned that invalidation of a condition would
also extend to the caregiver mental health and burden. Overall, caregivers of the survey reported
experiencing a moderate level of invalidation and experienced both discounting and lack of
understanding at similar levels. However, contrary to the hypothesized association, invalidation
was not found to be associated with overall caregiver burden or mental health. One of the
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explanations—discussed in the limitations section—for this might be lack of clarity regarding
when in the history of the diagnosis they experienced invalidation. Additionally, given that the
vast majority of participants were white women from middle-upper socioeconomic means, it
may be that they were more likely to be believed and supported (referred to specialists, medical
labs, etc.), and thus not invalidated by their medical provider. Another possibility is that the low
variability of invalidation in this small sample limited the ability to detect any correlation that
might exist. Finally, another reason for this outcome could be due to the general geographic
profile of the participants. Lyme disease originated in Connecticut and the primary Instagram
account used to recruit participants was also based out of Connecticut. This could indicate that
the location in which the participants live make it more likely that the symptoms of PTLDS
would be identified, thus resulting in a diagnosis and consequently less likelihood of
invalidation.
As mentioned above, another possibility is that the results were muddied by a lack of
clarity in the wording of the survey. The instructions for the 3*I asked participants to “rate the
frequency (‘Never’ to ‘Very Often’) of their experience with the statements provided.” Upon
reflection, it would have been prudent to specify at which point in their experience from which
they should be responding to the statements. For example, the level of invalidation experienced
before a PTLDS diagnosis would most likely be greater than after receiving the PTLDS
diagnosis as having the diagnosis is validation. As a result, the responses to this section may not
reflect that rate at which PTLDS caregivers experienced invalidation and whether that
invalidation contributed to their overall burden and mental health. Finally, it should be noted that
it was hypothesized that invalidation by medical providers would be an issue for PTLDS
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caregivers, and these results may reflect that diagnosis mitigates invalidation, or that invalidation
is not experienced by PTLDS caregivers in this sample.
Implications
The primary clinical implications of this study include expanded knowledge on the most
significant burdens for PTLDS caregivers. In the past, studies have looked at the experience of
caregivers of other chronic illnesses, but no studies have looked at the experience of the PTLDS
caregivers specifically as in the current study. Knowing that the most significant burdens regard
the mental toll of caregiving PTLDS individuals will aid medical professionals in recommending
resources such as therapy and support groups to the caregivers. Further support for mental health
treatment is evidenced by the anxiety and depression reported.
While the results of the invalidation inventory were not correlated with other measures as
hypothesized, caregivers still reported invalidation surrounding the diagnosis of their loved one.
Medical professionals must be aware of the impact of illness invalidation on patients and the
potential impact it could have on caregivers. Medical professionals must choose their language
carefully as to not imply lack of belief or discount information being given to them by the
PTLDS patient and their caregiver. This study continues to emphasize the importance of
considering the needs of caregivers, their burden and mental health. However, despite these
implications, the study was not without limitations.
Limitations
This study was subject to limiting factors that were both sociocultural due to the timing
of data collection, as well as specific limitations of study design and dissemination. The size of
the sample was also a limiting factor as it was too small and homogeneous to be generalizable to
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other populations. Additionally, the household income for the sample was above average and as
such, the results may not fully represent how finances affect burden, mental health, access to
care, and invalidation. Furthermore, the lack of diversity in this study made it difficult to
highlight specific struggles minorities may face when seeking access to healthcare. Research has
shown that when visiting doctors, racial minorities are met more frequently with disbelief and
passiveness than white patients (Armstrong et al., 2007). As mentioned above, the various
symptoms of PTLDS may require patients to see a variety of specialists before the diagnosis is
identified. This not only limits the care they receive, but also has the potential to increase
experiences of invalidation.
Another limitation was the wording in the illness invalidation inventory made it unclear
as to which time frame the participants were responding. More specific language regarding the
timing of the experience of invalidation could have had an impact on the results. After several
weeks of trying to recruit participants, it was brought to my attention that the term PTLDS was
looked upon negatively in the Lyme community and it was suggested that I use the term “chronic
Lyme disease” instead. This oversight caused the survey to be rejected by some accounts that
have thousands of followers and may have caused the study to lose otherwise willing
participants. Furthermore, dozens of support groups, online message boards, and other such
groups were contacted using the term PTLDS and there were no responses to the study. It is
unclear if using the term “chronic Lyme disease” instead would have had different results or
garnered additional participation. Taking this note and making the appropriate edits in the survey
opened the door for participants to feel safe completing the survey.
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As mentioned above, while the original measures were proven to have reliability and
validity, another limitation within this study lies in having to adapt them. Given this information,
the degree to which adaptation invalidated the measures in this study is unclear. While
Cronbach’s alpha on the current sample showed a high internal consistency, the measures were
not intended for or normed on PTLDS caregivers. An additional limitation of this study occurred
in the way the data was analyzed. Multiple correlations between major variables and subscales
were run, which increased the likelihood of family-wise errors and error rates may have been
inflated.
Finally, data collection occurred during the COVID-19 pandemic and may have had an
impact the results. First, the conditions of the pandemic made it challenging to use any other
methods of collecting data other than the internet. The isolated networking could have resulted in
the homogenous sample. Secondly, the collective trauma experienced during the pandemic may
have increased levels of anxiety and depression that was reflected in the participants. While the
survey did ask them about their mental health symptoms in relation to caregiving, it perhaps
could have been challenging for parents to identify the origin of their symptoms. Similarly,
parents across the country were experiencing harrowing caregiver burdens and increased
financial strain in response to schools closing and not being able to work. As such, the levels of
burden and financial concern being reported may have been influenced by this increased
demand. Additionally, the original dissemination process for this survey was affected by the
pandemic and therefore limited the already marginal population even more.
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Future Directions
Future directions for research include continuing to explore the specific burdens of the
PTLDS caregiver and the impact that caregiving has on their mental health. Further exploration
of specific interventions to target improving caregiver mental health and quality of life is
warranted. While this study was quantitative in nature, a future qualitative study would allow for
the identification of common burden themes of PTLDS caregivers. Future directions for research
should also include exploring the differences between various caregiver relationships
(parent–child, spouse–spouse, etc.) and how the experience among those relationships is similar
or different. This research could also examine the gender differences in the experience of
caregiving for PTLDS. This would help differentiate those burdens that are significant to PTLDS
caregivers in general and those that are significant to the specific caregiving relationship.
Future research should also include more detailed examinations about invalidation before
the PTLDS diagnosis and how that impacts caregiver burden and mental health and how, if at all,
the diagnosis improved functioning in those areas. Additionally, the groundbreaking project
coming out of Johns Hopkins may make PTLDS invalidation a thing of the past and future
research could look at caregiver mental health and burden before and after the diagnostic
procedure. Finally, future studies should include larger sample sizes and include more diversity
in areas of gender, ethnicity, and income.
Conclusion
With Lyme disease on the rise in the United States, it seems likely that incidences of
PTLDS will increase as well. Given the debilitating symptoms of PTLDS on the individual, it is
imperative that we consider the implications of the symptoms on the PTLDS caregiver. The
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results from this small sample seem to indicate that there is significant caregiver burden as well
as intense anxiety and depression symptoms experienced by the PTLDS caregiver. Given the
future positive direction of diagnosing PTLDS coming out of Johns Hopkins University, it seems
likely that invalidation will be experienced less among patients and caregivers. Implications of
future research could include providing psychoeducation to PTLDS caregivers, as well as access
to resources to ease burden and alleviate mental health symptoms. Caregiver burden involves a
cost to society and the individual that could be mitigated if resources were available from the
outset.
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Appendix A: Demographic Information
What is your current age? __________
What is your racial/ethnic background? (check all that apply)
American Indian/Alaska Native
Hispanic or Latinx

East Asian

South Asian

Black or African American

Native Hawaiian or other Pacific Islander

Middle Eastern/North African

Biracial

Multiracial

White/European Descent

Another:__________

What is your gender identity? (check all that apply)
Male
Queer

Female
Trans

Genderqueer

Non-Binary

Prefer not to say

Genderfluid

Two-spirit

Pangender

Another:__________

What is your sexual identity/sexual orientation?
Heterosexual

Gay

Lesbian

Unsure/Prefer Not to say

Bisexual

Pansexual

Queer

Asexual/Ace Spectrum

Another:___________

What is your marital status?
Married

Single (never married)

Divorced or Separated

In a domestic partnership

Widowed
What is your highest level of education?
Less than a high school diploma
BS)

High school degree or equivalent

Master’s degree (e.g. MA, MS, Med, etc.)

Bachelor’s degree (BA,

Doctorate (e.g. PhD, EdD, etc.)

Another:__________
What was your employment status before Lyme diagnosis?
Employed full-time (40+ hours a week)
Unemployed (was looking for work)
Retired

Self-employed

Employed part-time (less than 40 hours a week)

Unemployed (was not looking for work)

Student

Unable to work: Explain___________________

What is your current employment status?
Employed full-time (40+ hours a week)
Unemployed (was looking for work)
Retired

Self-employed

Employed part-time (less than 40 hours a week)

Unemployed (was not looking for work)

Unable to work: Explain___________________

What is your household income? ___________
What is the current age of the person you are caring for? __________

Student

40

What is your relationship to the patient? __________
Do you have caregiving help?
No

Yes

If yes, who is helping you?
Spouse

Co-parent

Grandparent

Healthcare professional

Other family member: __________

Another:__________

On average, how many hours per week do you spend caregiving?
Less than 5

5-10

10-15

15-20

20-25

25-30

Over 30

Domestic worker
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Appendix B: Tables
Table B1
Demographic Characteristics
Gender
Female

Percent (%)
100%

Count
30

Sexuality
Heterosexual

100%

30

Racial/Ethnic Background
White/European Descent
Hispanic/Latinx
Prefer not to say

93.3%
3.3%
3.3%

28
1
1

Marital Status
Married
Single (never married)
Divorced or separated
In a domestic partnership

73.3%
3.3%
16.7%
6.7%

22
1
5
2

Age
20-29
30-49
50-72

3%
57%
40%

1
17
12

Yearly Household Income
Less than $20,000
$20,000-$34,999
$35,000-$49,999
$50,000-$74,999
$75,000-$99,999
$100,000-$149,999
$150,000-$199,999
$200,000 or more

7.1%
3.6%
7.1%
14.3%
14.3%
32.1%
10.7
10.7

2
1
2
4
4
9
3
3

Employment Status Before
Caregiving
Employed full-time (40+)
Employed part-time (<40)

36.7%
20%

11
6

42

Unemployed (not looking for
work)
Retired
Self-employed
Unable to work

10%

3

6.7%
23.3%
3.3%

2
7
1

26.7%
20%
6.7%

8
6
2

10%
16.6%
20%

3
5
6

Average Hours Spent
Caregiving
Less than 5
5-10
11-15
16-20
21-25
25-30
Over 30

20%
6.7%
10%
13.3%
6.7%
10%
33.3%

6
2
3
4
2
3
10

Total

100%

30

Employment Status Before
Caregiving
Employed full-time (40+)
Employed part-time (<40)
Unemployed (not looking for
work)
Retired
Self-employed
Unable to work
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Table B2
Descriptive Statistics for CQOLL Item Averages in Descending Order

1. It upsets me to see my
loved one deteriorate.
2. My level of stress and
worries has increased.
3. REI have more of a
positive outlook on life
since my loved one’s
illness.
4. I feel frustrated.
5. REI am satisfied with the
support I get from my
family.
6. I feel under increased
mental strain.
7. I fear the adverse effects
of treatment on my loved
one.
8. REI am satisfied with my
sex life.
9. The need to manage my
loved one’s pain is
overwhelming.
10. REFamily
communication has
increased.
11. I worry about the impact
my loved one’s illness has
had on my children or other
family members.
12. I am under a financial
strain.
13. REI get support from
my friends and neighbors.
14. I feel sad.
15. I feel nervous.
16. It is challenging to
maintain my outside
interests.

N
30

Minimum Maximum Mean
2
5
4.53

Std. Deviation
.82

30

1

5

4.27

1.20

30

1

5

4.07

1.44

30
30

1
2

5
5

3.80
3.80

1.35
1.06

30

1

5

3.70

1.34

30

1

5

3.70

1.34

30

1

5

3.63

1.49

30

1

5

3.53

1.36

30

1

5

3.53

1.43

30

1

5

3.50

1.36

30

1

5

3.47

1.57

30

1

5

3.47

1.31

30
30
30

1
1
1

5
5
5

3.47
3.43
3.40

1.28
1.35
1.19

44

17. I am concerned about
our insurance coverage.
18. REMy sense of
spirituality has increased.
19. My economic future is
uncertain.
20. The responsibility I
have for my loved one’s
care at home is
overwhelming.
21. REI feel validated by
my loved one’s healthcare
provider.
22. I am discouraged about
the future.
23. My sleep is less restful.
24. I feel guilty.
25. It bothers me, limiting
my focus to day-to-day.
26. My daily life is imposed
upon.
27. REI feel adequately
informed about my loved
one’s illness.
28. It bothers me that other
family members have not
shown interest in taking
care of my loved one.
29. I have difficulty dealing
with my loved one’s
changing eating habits.
30. It bothers me that my
daily routine is altered.
31. REI have developed a
close relationship with my
loved one.
32. REI am glad that my
focus is on getting my loved
one well.
33. It bothers me that my
priorities have changed.
34. The need to protect my
loved one bothers me.

N
30

Minimum Maximum Mean
1
5
3.37

Std. Deviation
1.69

30

1

5

3.33

1.67

30

1

5

3.23

1.65

30

1

5

3.23

1.48

30

1

5

3.23

1.63

30

1

5

3.13

1.33

30
30
30

1
1
1

5
5
5

3.13
3.07
3.07

1.25
1.53
1.23

30

1

5

3.00

1.46

30

1

5

2.87

1.58

30

1

5

2.77

1.52

30

1

5

2.53

1.36

30

1

5

2.53

1.17

30

1

5

2.47

1.33

30

1

5

2.27

1.28

30

1

5

2.17

1.34

30

1

5

1.47

1.29

45

35. It bothers me that I need
to be available to drive my
loved one to appointments.
Valid N (listwise)

N
30

Minimum Maximum Mean
1
4
1.47

Std. Deviation
.900

30

Note: This table lists the most significant burdens for PTLDS caregivers. RE items have been
recoded
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Table B3
Correlation Matrix Displaying Correlations Between all Major Variables
Variable

n

M

SD

1

19.16

-

22.50

.255

-

3.PHQ30 23.53
11.66
ADS
4.3*I
30 26.20
7.49
Note. ** significant at the 0.01 level

.313

.531**

-

.446

.376

.342

1.Horowitz 30 86.60
LymeMSIDS
2.CQOLL 30 109.37

2

3

4

-

